期刊文献+

重庆市耐多药结核分枝杆菌二线注射类药物交叉耐药情况分析 被引量:2

Cross-resistance to second-line injectable drugs among multidrug- resistant Mycobacterium tuberculosis isolates in Chongqing, China
原文传递
导出
摘要 目的了解重庆市耐多药结核病(multidrug-resistant tuberculosis,MDR-TB)临床菌株二线注射类药物的耐药性及交叉耐药情况,为重庆市MDR-TB患者合理选择注射类药物进行治疗提供依据。方法收集2015年1月至2017年6月重庆市39个区(县)MDR-TB患者结核分枝杆菌临床分离株229株,通过微量肉汤稀释法检测卡那霉素(kanamycin,Km)、阿米卡星(amikacin,Am)和卷曲霉素(capreomycin,Cm)的敏感性,分析耐药及交叉耐药情况,并用PCR测序方法对交叉耐药菌株进行基因分析。结果在229株MDR菌株中,Km和Am交叉耐药27株,分别占79.41%(27/34)、100.00%(27/27);Km、Am与Cm交叉耐药18株,分别占Km、Am和Cm耐药株的52.94%(18/34)、66.67%(18/27)和94.74%(18/19)。在27株Km和Am及18株Km、Am和Cm交叉耐药株中,rrs基因A1401G突变率分别为74.07%、72.22%,均高于其他基因突变(P<0.01)。结论rrs基因A1401G突变是Km、Am与Cm交叉耐药的分子基础。Km和Am、Km和Cm间均为部分交叉耐药,对Km耐药者,可选用Am和Cm进行治疗。 Objective To understand the resistance and cross-resistance to second-line injectable drugs(SLIDs)of multidrug-resistant Mycobacterium tuberculosis(MDR-TB)isolates in SLIDs to treat MDR-TB patients.Methods Two hundred and twenty-nine MDR-TB clinical strains were collected from 39 Districts(Counties)of Chongqing during January 2015 and June 2017 and drug susceptibility to kanamycin(Km),amikacin(Am)and capreomycin(Cm)were determined using microdilution test.Cross-resistant MDR-TB strains were sequenced for rrs gene mutation.Results Of 229 MDR-TB isolates,27 were cross-resistant to Km and Am,accounting for 79.41%(27/34)and 100.00%(27/27)with A1401 G mutation rate in rrs of 74.07%.18 isolates were found to be cross-resistant to Km,Am and Cm,accounting for 52.94%(18/34),66.67%(18/27)and 94.74%(18/19),respectively with A1401 G mutation rate of 74.07%.The overall mutation rate of rrs gene was higher than that of other genes(P<0.01).Conclusions A1401 G mutation in rrs is the leading cause of cross-resistance of MDR-TB isolates to SLIDs in Chongqing.The drug resistances to Km,Am and Km,Cm were partial,therefore,for the Km-resistant isolates,Am and Cm can be used for MDR-TB treatment.
作者 沈静 陈林 胡彦 刘洁 SHEN Jing;CHEN Lin;HU Yan;LIU Jie(Tuberculosis Reference Laboratory of Chongqing Tuberculosis Control Institute,Chongqing 400050,China)
出处 《中国预防医学杂志》 CAS CSCD 2020年第8期874-878,共5页 Chinese Preventive Medicine
基金 重庆市基础研究与前沿探索项目(cstc2018jcyjAX0589) 重庆市卫生计生委医学科研项目(2016MSXM106)
关键词 结核分枝杆菌 卡那霉素 阿米卡星 卷曲霉素 交叉耐药 Mycobacterium tuberculosis Kanamycin Amikacin Capreomycin Cross-resistance
  • 相关文献

参考文献2

二级参考文献17

  • 1张国龙,杜长梅,苍泽卓也,池田雄史,王伟,石瑞如.中日合作对河南省结核菌二线药物耐药监测研究[J].医药论坛杂志,2005,26(19):14-16. 被引量:15
  • 2社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3038
  • 3World Health Organization.Multidrug and extensively drug-resistant TB(M/XDR-TB):2010 global report on surveillance and response.Geneva:WHO,2010:5-10.
  • 4World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva:WHO,2006:38-52.
  • 5Centers for Disease Control and Prevention (CDC).Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide,2000-2004.MMWR Morb Mortal Wkly Rep,2006,55:301-305.
  • 6Jeon CY,Hwang SH,Min JH,et al.Extensively drug-resistant tuberculosis in South Korea:risk factors and treatment outcomes among patients at a tertiary referral hospital.Clin Infect Dis,2008,46:42-49.
  • 7Toungoussova OS,Mariandyshev AO,Bjune G,et al.Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast,Russia,to second-line anti-tuberculosis drugs.Eur J Clin Microbiol Infect Dis,2005,24:202-206.
  • 8Abubakar I,Moore J,Drobniewski F,et al.Extensively drug-resistant tuberculosis in the UK:1995 to 2007.Thorax,2009,64:512-515.
  • 9Banerjee R,Allen J,Westenhouse J,et al.Extensively drug-resistant tuberculosis in california,1993-2006.Clin Infect Dis,2008,47:450-457.
  • 10Long R,Chong H,Hoeppner V,et al.Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.Clin Infect Dis,2009,48:1354-1360.

共引文献28

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部